Status:
NOT_YET_RECRUITING
The Efficacy and Safety of Guilu Erxian Jiao in the Treatment of Intradialytic Hypotension
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Intradialytic Hypotension
End-Stage Renal Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to learn if Guilu Erxian Jiao, a traditional Chinese herbal medicine, can help manage intradialytic hypotension (IDH), a drop in blood pressure that occurs during he...
Detailed Description
1. Clinical Background and Study Rationale Intradialytic hypotension (IDH) is defined as a decrease in systolic blood pressure of more than 20 mmHg or a drop of more than 10 mmHg in mean arterial ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Undergoing maintenance hemodialysis three times per week, 4 hours per session
- History of intradialytic hypotension (IDH)
- Willing and able to provide written informed consent
Exclusion
- Pregnant or lactating women
- Severe comorbid illness, such as cancer, stroke, or liver cirrhosis
- Inability to comply with study medication regimen
- Regular use of antihypertensive medication
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2028
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06980922
Start Date
June 1 2025
End Date
May 31 2028
Last Update
May 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keelung Chang Gung Memorial Hospital
Keelung, Taiwan